Moderna (MRNA)
(Delayed Data from NSDQ)
$122.17 USD
+0.06 (0.05%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $122.20 +0.03 (0.02%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
MRNA 122.17 +0.06(0.05%)
Will MRNA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRNA
Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?
5 Biotech Stocks to Bet On Bright Industry Prospects
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
Other News for MRNA
Russell Top 200 stocks with positive implied growth + positive expected surprises - Citi
Global company events calendar
GSK and Flagship Pioneering partner to discover novel medicines and vaccines
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q2 2024 Update
iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum